Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.

iScience·2026

Same author

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.

Digital discovery·2026

Same author

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Journal of medicinal chemistry·2026

Same author

Progress and new challenges in image-based profiling.

Molecular systems biology·2026

Same author

High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration.

Frontiers in bioengineering and biotechnology·2026

Same author

High content 3D imaging by dual-view oblique plane microscopy.

PNAS nexus·2025

Same journal

Recent advances in 1,3,5-triazine-based PI3K inhibitors for cancer therapy: a comprehensive review.

Future medicinal chemistry·2026

Same journal

Indole-based carbohydrazides as potent anti-proliferative leads and tubulin polymerization inhibitors: design, synthesis, cytotoxic evaluation, <i>in silico</i> ADMET and docking studies.

Future medicinal chemistry·2026

Same journal

Recent advances in the development of small molecule STK33 inhibitors.

Future medicinal chemistry·2026

Same journal

Biological evaluation and molecular docking of previously reported pyrazolo-thiazole derivatives as dual α-amylase and α-glucosidase inhibitors.

Future medicinal chemistry·2026

Same journal

Coumarin derivatives as antidiabetic agents: a comprehensive review on mechanistic insights, structure-activity relationships, <i>in silico</i> studies, and challenges.

Future medicinal chemistry·2026

Same journal

Expanding the tetrazole space: medicinal chemistry, biological diversity and structure-activity relationships.

Future medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Next-generation phenotypic screening.

Scott J Warchal¹, Asier Unciti-Broceta¹, Neil O Carragher¹

¹Cancer Research UK Edinburgh Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.

Future Medicinal Chemistry

|July 1, 2016

Summary

This summary is machine-generated.

Modern phenotypic drug discovery (PDD) advances overcome traditional screening challenges. New technologies enable efficient identification of drug candidates by focusing on observable effects rather than known targets.

Keywords:

high content image informatics mechanism of action pathway profiling phenotypic screening target deconvolution transcriptomics

More Related Videos

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Mar 18, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

Drug discovery and development
Pharmacology
Biotechnology

Background:

Phenotypic drug discovery (PDD) identifies drug candidates based on observable effects, not target knowledge.
Traditional PDD faces challenges in screening and selection efficiency.
Advancements in technology offer new opportunities for PDD.

Purpose of the Study:

To outline challenges in traditional phenotypic screening.
To propose solutions and opportunities using modern PDD technologies.
To provide a prospective view of the future of PDD.

Main Methods:

Review of historical and recent examples of drugs discovered via PDD.
Highlighting technological advances in in vitro models, high-content imaging, and image informatics.
Discussing mechanism-of-action profiling and target deconvolution techniques.

Main Results:

Modern PDD technologies address limitations of traditional screening.
Numerous approved drugs and candidates have been identified using PDD.
Technological integration enhances the efficiency and scope of PDD.

Conclusions:

Modern PDD, supported by technological innovation, represents a new era in drug discovery.
Advances in in vitro models, imaging, and computational analysis are key drivers.
PDD continues to be a vital strategy for identifying novel therapeutics.